Affymax shares plunge on PhIII cardio issues for Hematide

Affymax says that a slate of four late-stage trials for its anemia drug Hematide demonstrated that the therapy is non-inferior to Amgen's Epogen and Aranesp, hitting its primary endpoints and putting it on a path to file for an FDA approval. But a stumble on cardio risks in a key sub-group of patients captured the unwelcome attention of analysts, with AFFY shares plunging 65 percent this morning. Altogether 2,609 patients were studied in the four late-stage studies in Europe and the U.S., with...